Announced details
Medical support business; blood-derived processing
The number of partner clinics increased from 153 in 2023 to 800 in April 2026. The CAGR for the most recent 3 years exceeded 70%, and the number of partner clinics increased more than fivefold.
More than 800 partner clinics as of April 2026; 153 in 2023, 445 in 2024 and 685 in 2025
Partnership based on ongoing business relationships with medical institutions
The company considers the impact on performance for the fiscal year ending September 2026 to be limited, but states that the service will contribute to improved performance over the medium to long term.
The company does not address Contract Value / Offering price.
“Supplementary Explanatory Materials for the Fiscal Year Ending September 2026 Financial Results,” disclosed on 12 February 2026
| Item | Details |
|---|---|
| Names of Products / Services Covered | Blood-derived processing service “PDF-FD” |
| Relationship with the Company | Partnership based on ongoing business relationships with medical institutions |
| Applicable area | Medical support business; blood-derived processing |
| Quantitative Effects | The number of partner clinics increased from 153 in 2023 to 800 in April 2026. The CAGR for the most recent 3 years exceeded 70%, and the number of partner clinics increased more than fivefold. |
| Usage history | More than 800 partner clinics as of April 2026; 153 in 2023, 445 in 2024 and 685 in 2025 |
| Impact on Business Performance | The company considers the impact on performance for the fiscal year ending September 2026 to be limited, but states that the service will contribute to improved performance over the medium to long term. |
| Source | “Supplementary Explanatory Materials for the Fiscal Year Ending September 2026 Financial Results,” disclosed on 12 February 2026 |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explains that the increase in partner clinics will contribute to the expansion of its recurring revenue base, the emergence of network effects, the accumulation of cases, data and know-how, and the strengthening of its competitive advantage.